文献速递肺栓塞与肺血管病

多生物标志物模型与临床肺动脉高压生存风险模型的等效性

Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
PubMed 文献 · Chest · 2024-08-16

本研究在训练(n=1,623)、测试(n=696)和验证(n=237)队列中,用6种血液生物标志物(不含NT-proBNP)构建聚类模型,并与REVEAL、ESC/ERS等临床风险模型比较。结果显示生物标志物模型单独区分风险的能力与REVEAL等效(AUC 0.74),联合NT-proBNP或加入临床评分可提升预测性能。

要点

  • 多生物标志物模型单独使用与REVEAL风险模型等效(AUC 0.74)。
  • 生物标志物模型联合NT-proBNP或加入临床评分可改善风险预测。
  • 血液标志物模型可能支持更频繁的无创风险监测。

核心结论

  • 多生物标志物模型单独使用与当前PAH临床死亡风险预测模型等效,联合NT-proBNP或加入临床评分时预测性能提升。

研究设计与样本

  • 使用多重酶联免疫吸附试验测量NT-proBNP、IL-6、内皮抑素、半乳糖凝集素3、肝癌衍生生长因子及IGFBP1-7等标志物。
  • 训练队列n=1,623,测试队列n=696,验证队列n=237。
  • 采用主成分分析、无监督k-means聚类,以Kaplan-Meier和Cox回归分析无移植生存。

主要发现

  • 算法基于6种生物标志物、体重、身高和PAH诊断年龄生成5个聚类,风险区分良好。
  • 在测试和验证队列中,生物标志物模型单独使用与REVEAL等效(AUC 0.74)。
  • 将生物标志物模型加入ESC/ERS评分和REVEAL评分可改善这两个评分。

关键数值与推荐

  • 生物标志物模型联合NT-proBNP调整后的模型C统计量、AIC和校准最佳,优于单独生物标志物模型或单独NT-proBNP模型。
  • 生物标志物模型单独使用AUC为0.74,与REVEAL等效。

临床怎么用

  • 临床风险评分预测良好但需多项检查,加入血液生物标志物可改善预测或支持更频繁的无创风险监测。
  • 生物标志物模型可作为PAH风险分层和治療决策支持的补充工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk assessment in pulmonary arterial hypertension (PAH) is fundamental to guiding treatment and improved outcomes. Clinical models are excellent at identifying high-risk patients, but leave uncertainty amongst moderate-risk patients. RESEARCH QUESTION: Can a multiple blood biomarker model of PAH, using previously described biomarkers, improve risk discrimination over current models? STUDY DESIGN AND METHODS: Using a multiplex enzyme-linked immunosorbent assay, we measured N-terminal pro-B-type natriuretic peptide (NT-proBNP), soluble suppressor of tumorigenicity, IL-6, endostatin, galectin 3, hepatoma derived growth factor, and insulin-like growth factor binding proteins (IGFBP1-7) in training (n = 1,623), test (n = 696), and validation (n = 237) cohorts. Clinical variables and biomarkers were evaluated by principal component analysis. NT-proBNP was not included to develop a model independent of NT-proBNP. Unsupervised k-means clustering classified participants into clusters. Transplant-free survival by cluster was examined using Kaplan-Meier and Cox proportional hazard regressions. Hazard by cluster was compared with NT-proBNP, Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL), and European Society of Cardiology and European Respiratory Society risk models alone and combined clinical and biomarker models. RESULTS: The algorithm generated five clusters with good risk discrimination using six biomarkers, weight, height, and age at PAH diagnosis. In the test and validation cohorts, the biomarker model alone performed equivalent to REVEAL (area under the receiver operating characteristic curve, 0.74). Adding the biomarker model to the European Society of Cardiology and European Respiratory Society score and REVEAL score improved the European Society of Cardiology and European Respiratory Society score and REVEAL score. The best overall model was the biomarker model adjusted for NT-proBNP with the best C statistic, Akaike information criterion, and calibration for the adjusted model compared with either the biomarker or NT-proBNP model alone. INTERPRETATION: In this study, a multibiomarker model alone was equivalent to current PAH clinical mortality risk prediction models and improved performance when combined and added to NT-proBNP. Clinical risk scores offer excellent predictive models, but require multiple tests; adding blood biomarkers to models can improve prediction or can enable more frequent, noninvasive monitoring of risk in PAH to support therapeutic decision-making.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Griffiths M, Simpson CE, Yang J, et al. Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models. Chest. 2024. PMID: 39154795. doi:10.1016/j.chest.2024.06.3824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。